-
1 week ago | 
pharmacytimes.com | Aislinn Antrim |Alexandra Gerlach |Luke Halpern
Executive Order Aims to Lower Prescription Drug CostsPresident Donald J. Trump has signed an executive order that aims to reduce drug costs for Americans and tie them to what other nations pay for medications.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Fixed-duration, first-line ibrutinib (Imbruvica; Janssen Biotech) plus venetoclax (Vexclexta; AbbVie and Genentech) demonstrated durable progression-free survival (PFS) and overall survival (OS) in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic leukemia (SLL) with high-genomic features.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Listen to the final episode in our Pharmacy Times Peer Exchange feature series on antibody drug conjugates and HER2 breast cancer. In this segment, our pharmacy experts share how they have discussions with patients about treatment and interdisciplinary approaches to managing side effects to enhance patient care.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) characterized by significant bone marrow scarring, extramedullary hematopoiesis, recurrent splenomegaly, and anemia due to a progressive reduction in generation of red blood cells. MF is incurable, so treatment is focused on disease control and improving quality of life.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Multiple myeloma (MM) is an incurable, clonal plasma cell proliferative disorder, accounting for over 35,780 cases in the United States in 2024.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Toxicities are a common occurrence in patients with breast cancer (BC) being treated with novel therapies like endocrine therapies, targeted therapies, or immunotherapies. This can make treatment challenging as clinicians aim to treat the patient’s cancer alongside managing toxicities in a way that does not impair the integrity of those cancer therapies. Shared decision-making is also crucial when managing toxicities, as patients are typically on these treatments for a long time.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Measuring minimal residual disease (MRD) is a growing area of interest in the treatment landscape of multiple myeloma (MM), an incurable hematologic malignancy characterized by increasingly poorer responses as patients progress through therapy. MRD testing can be a useful tool and give valuable insights into disease status, helping guide more personalized treatment strategies.
-
3 weeks ago | 
managedhealthcareexecutive.com | Alexandra Gerlach
This article was originally published by Pharmacy Times. Deeper knowledge of the integral relationship between the gut and cancer therapy is critical for maintaining the integrity and efficacy of agents that have revolutionized cancer treatment over the past few decades. At the 2025 ASCO Annual Meeting this weekend, experts discussed the complexity of the gut microbiota and emerging research highlighting its role in modulating treatment response and resistance mechanisms.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
The tumor microenvironment (TME) is a heterogeneous and dynamic ecosystem where immune cells and tumor cells interact in ways that either promote or suppress cancer progression. At the 2025 ASCO Annual Meeting, researchers emphasized how the immune system’s role within the TME is shaped by this complexity, highlighting the roles of both pro-tumor and anti-tumor forces that influence therapeutic outcomes. Their insights reveal how the TME can be manipulated to improve immunotherapy responses.
-
3 weeks ago | 
pharmacytimes.com | Alexandra Gerlach
Resistance remains one of the most significant barriers to optimal treatment outcomes and overall survival for patients across cancer types. Although genetic mutations play a key role in poor therapeutic responses, the gut microbiome may also interfere with critical therapies in the cancer treatment landscape. Studies show that disruptions in gut microbiota are associated with resistance and less favorable responses to immunotherapies.
